US Food and Drug Administration officials may allow some wiggle room with the coronavirus vaccine safety recommendations that garnered the ire from the White House in recent days.
US FDA ‘Flexible’ With Vaccine Safety Data Requirements, CBER’s Peter Marks Says
The median of two months of follow-up is not absolute, but agency flexibility is limited.
